Free Webex Call
Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
1 of 3
“The Asia-Pacific Biosimilar Insulin Glargine & Lispro Market is Forecast to Reach $ 786 Million By 2024.”
FEATURED COMPANIES
- Biocon Limited
- Cipla Limited
- Eli Lily and Company
- Julphar Diabetes LLC
- Merck & Co.
- Novo Nordisk A/S
- MORE
Biosimilar is a biological product which is similar to the reference product, already approved by authorities and marketed by companies other than the patent holder company. Insulin is a hormone produced by pancreatic cell which is responsible for absorption of glucose from the blood. Lack of insulin in the body causes diabetes. Insulin is available in different forms depending upon the sources such as animal derived, chemically synthesized or produced through recombinant technology. Insulin can be categorized as fast acting, immediate acting and long acting depending upon the absorption of insulin from the blood in the body. Glargine and lispro are two types of insulin.
The Asia-Pacific Biosimilar Insulin Glargine & Lispro Market is forecast to reach $ 786 million by 2024. Increasing expenditure on healthcare, changing eating habits and growing adoption of sedentary lifestyle are increasing the prevalence of obesity and diabetes, which in turn is driving the sales of biosimilar insulin. Additionally, increasing dependence on packaged food is further fueling growth of the market.
The Asia-Pacific Biosimilar Insulin Glargine & Lispro Market is segmented based on end-user, country and company. Based on end-user, the market can be bifurcated into Type 1 Diabetes and Type 2 Diabetes, of which the former segment dominates the market since it is an autoimmune disorder and the body does not produce any insulin.
The major players operating in the biosimilar insulin glargine & lispro market are Sanofi S.A., Eli Lilly and Company, Biocon Limited, Novo Nordisk A/S, Wockhardt, Cipla Limited, Merck Limited, and others. Major companies are developing advanced technologies and launching new products in order to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new product developments.
Years considered for this report:
Historical Years: 2014-2017
Base Year: 2018
Estimated Year: 2019
Forecast Period: 2020–2024
Objective of the Study:
The market size of the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market was calculated by using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years.
These values were sourced from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.
Key Target Audience:
Report Scope:
In this report, the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Market, by End-User:
Company Profiles: Detailed analysis of the major companies present in the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market.
Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
The Asia-Pacific Biosimilar Insulin Glargine & Lispro Market is forecast to reach $ 786 million by 2024. Increasing expenditure on healthcare, changing eating habits and growing adoption of sedentary lifestyle are increasing the prevalence of obesity and diabetes, which in turn is driving the sales of biosimilar insulin. Additionally, increasing dependence on packaged food is further fueling growth of the market.
The Asia-Pacific Biosimilar Insulin Glargine & Lispro Market is segmented based on end-user, country and company. Based on end-user, the market can be bifurcated into Type 1 Diabetes and Type 2 Diabetes, of which the former segment dominates the market since it is an autoimmune disorder and the body does not produce any insulin.
The major players operating in the biosimilar insulin glargine & lispro market are Sanofi S.A., Eli Lilly and Company, Biocon Limited, Novo Nordisk A/S, Wockhardt, Cipla Limited, Merck Limited, and others. Major companies are developing advanced technologies and launching new products in order to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new product developments.
Years considered for this report:
Historical Years: 2014-2017
Base Year: 2018
Estimated Year: 2019
Forecast Period: 2020–2024
Objective of the Study:
- To analyze and forecast the market size of the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market.
- To classify and forecast the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market based on end-user, company and country distribution.
- To identify drivers and challenges for the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market.
- To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market.
- To conduct pricing analysis for the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market.
- To identify and analyze the profile of leading players operating in the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market.
The market size of the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market was calculated by using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years.
These values were sourced from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.
Key Target Audience:
- Biosimilar insulin glargine & lispro manufacturers, suppliers, distributors and other stakeholders
- Government bodies such as regulating authorities and policy makers
- Organizations, forums and alliances related to insulin glargine & lispro
- Market research and consulting firms
Report Scope:
In this report, the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Market, by End-User:
- Type 1 Diabetes
- Type 2 Diabetes
- Japan
- China
- India
- South Korea
- Bangladesh
- Pakistan
Company Profiles: Detailed analysis of the major companies present in the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market.
Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Note: Product cover images may vary from those shown
2 of 3
FEATURED COMPANIES
- Biocon Limited
- Cipla Limited
- Eli Lily and Company
- Julphar Diabetes LLC
- Merck & Co.
- Novo Nordisk A/S
- MORE
1. Product Overview
2. Research Methodology
3. Executive Summary
4. Voice of Customer
4.1. Brand Awareness
4.2. Factors Influencing Purchase Decision
4.3. Unmet Needs & Challenges
5. Global Biosimilar Insulin Market Overview
6. APAC Insulin Glargine & Lispro Market Outlook
6.1. Market Size & Forecast, (2014-2024)
6.1.1. By Value (USD Million) & Volume (Million Units)
6.2. Market Share & Forecast (2014-2024)
6.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.2.2. By Country (China, Japan, India, Australia, South Korea, ASEAN, Bangladesh, Pakistan & Others)
6.2.3. By Company (2018)
6.3. Market Attractiveness Index
6.4. Competition Outlook
6.4.1. Major Insulin Glargine & Lispro Suppliers with products registered and sold
6.5. Country Analysis
6.5.1. China Insulin Glargine & Lispro Market Outlook
6.5.1.1. Market Size & Forecast
6.5.1.1.1. By Value & Volume
6.5.1.2. Market Share & Forecast
6.5.1.2.1. By End User
6.5.2. Japan Insulin Glargine & Lispro Market Outlook
6.5.2.1. Market Size & Forecast
6.5.2.1.1. By Value & Volume
6.5.2.2. Market Share & Forecast
6.5.2.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.3. India Insulin Glargine & Lispro Market Outlook
6.5.3.1. Market Size & Forecast
6.5.3.1.1. By Value & Volume
6.5.3.2. Market Share & Forecast
6.5.3.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.4. South Korea Insulin Glargine & Lispro Market Outlook
6.5.4.1. Market Size & Forecast
6.5.4.1.1. By Value & Volume
6.5.4.2. Market Share & Forecast
6.5.4.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.5. Australia Insulin Glargine & Lispro Market Outlook
6.5.5.1. Market Size & Forecast
6.5.5.1.1. By Value & Volume
6.5.5.2. Market Share & Forecast
6.5.5.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.6. ASEAN Insulin Glargine & Lispro Market Outlook
6.5.6.1. Market Size & Forecast
6.5.6.1.1. By Value & Volume
6.5.6.2. Market Share & Forecast
6.5.6.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.7. Pakistan Insulin Glargine & Lispro Market Outlook
6.5.7.1. Market Size & Forecast
6.5.7.1.1. By Value & Volume
6.5.7.2. Market Share & Forecast
6.5.7.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.8. Bangladesh Insulin Glargine & Lispro Market Outlook
6.5.8.1. Market Size & Forecast
6.5.8.1.1. By Value & Volume
6.5.8.2. Market Share & Forecast
6.5.8.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
7. Market Dynamics
7.1. Drivers
7.2. Challenges
8. Market Trends & Developments
9. Porter's Five Forces Analysis
9.1. Bargaining Power of Suppliers
9.2. Bargaining Power of Consumers
9.3. Threat of New Suppliers
9.4. Threat of Substitute
9.5. Competitive Rivalry
10. Competitive Landscape
10.1. Competition Outlook
10.2. Company Profiles
10.2.1. Basic Financial Details (Revenue, Gross Profit, Net Profit)
10.2.2. Sales Value and Volume of Product of Interest
10.2.3. Key Strategies
10.2.3.1. New Products Launches
10.2.3.2. Product Development Plan
10.2.3.3. Expansion Plan
10.2.4. Supply Chain Analysis
10.2.5. Business Distribution
10.2.6. SWOT Analysis
11. Timelines from Drug Development to Commercial Launch
12. Strategic Recommendations
List of Figures:
Figure 1: APAC Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F (USD Million)
Figure 2: APAC Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 4: APAC Diabetic Population Share, 2017
Figure 3: Japan Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 4: Japan Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 5: China Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 6: China Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 7: India Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 8: India Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 9: South Korea Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 10: South Korea Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 11: Bangladesh Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 12: Bangladesh Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 13: Pakistan Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 14: Pakistan Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 15: APAC Biosimilar Insulin Glargine and Lispro Pricing Analysis, 2014-2024F
2. Research Methodology
3. Executive Summary
4. Voice of Customer
4.1. Brand Awareness
4.2. Factors Influencing Purchase Decision
4.3. Unmet Needs & Challenges
5. Global Biosimilar Insulin Market Overview
6. APAC Insulin Glargine & Lispro Market Outlook
6.1. Market Size & Forecast, (2014-2024)
6.1.1. By Value (USD Million) & Volume (Million Units)
6.2. Market Share & Forecast (2014-2024)
6.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.2.2. By Country (China, Japan, India, Australia, South Korea, ASEAN, Bangladesh, Pakistan & Others)
6.2.3. By Company (2018)
6.3. Market Attractiveness Index
6.4. Competition Outlook
6.4.1. Major Insulin Glargine & Lispro Suppliers with products registered and sold
6.5. Country Analysis
6.5.1. China Insulin Glargine & Lispro Market Outlook
6.5.1.1. Market Size & Forecast
6.5.1.1.1. By Value & Volume
6.5.1.2. Market Share & Forecast
6.5.1.2.1. By End User
6.5.2. Japan Insulin Glargine & Lispro Market Outlook
6.5.2.1. Market Size & Forecast
6.5.2.1.1. By Value & Volume
6.5.2.2. Market Share & Forecast
6.5.2.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.3. India Insulin Glargine & Lispro Market Outlook
6.5.3.1. Market Size & Forecast
6.5.3.1.1. By Value & Volume
6.5.3.2. Market Share & Forecast
6.5.3.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.4. South Korea Insulin Glargine & Lispro Market Outlook
6.5.4.1. Market Size & Forecast
6.5.4.1.1. By Value & Volume
6.5.4.2. Market Share & Forecast
6.5.4.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.5. Australia Insulin Glargine & Lispro Market Outlook
6.5.5.1. Market Size & Forecast
6.5.5.1.1. By Value & Volume
6.5.5.2. Market Share & Forecast
6.5.5.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.6. ASEAN Insulin Glargine & Lispro Market Outlook
6.5.6.1. Market Size & Forecast
6.5.6.1.1. By Value & Volume
6.5.6.2. Market Share & Forecast
6.5.6.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.7. Pakistan Insulin Glargine & Lispro Market Outlook
6.5.7.1. Market Size & Forecast
6.5.7.1.1. By Value & Volume
6.5.7.2. Market Share & Forecast
6.5.7.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.8. Bangladesh Insulin Glargine & Lispro Market Outlook
6.5.8.1. Market Size & Forecast
6.5.8.1.1. By Value & Volume
6.5.8.2. Market Share & Forecast
6.5.8.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
7. Market Dynamics
7.1. Drivers
7.2. Challenges
8. Market Trends & Developments
9. Porter's Five Forces Analysis
9.1. Bargaining Power of Suppliers
9.2. Bargaining Power of Consumers
9.3. Threat of New Suppliers
9.4. Threat of Substitute
9.5. Competitive Rivalry
10. Competitive Landscape
10.1. Competition Outlook
10.2. Company Profiles
10.2.1. Basic Financial Details (Revenue, Gross Profit, Net Profit)
10.2.2. Sales Value and Volume of Product of Interest
10.2.3. Key Strategies
10.2.3.1. New Products Launches
10.2.3.2. Product Development Plan
10.2.3.3. Expansion Plan
10.2.4. Supply Chain Analysis
10.2.5. Business Distribution
10.2.6. SWOT Analysis
11. Timelines from Drug Development to Commercial Launch
12. Strategic Recommendations
List of Figures:
Figure 1: APAC Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F (USD Million)
Figure 2: APAC Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 4: APAC Diabetic Population Share, 2017
Figure 3: Japan Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 4: Japan Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 5: China Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 6: China Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 7: India Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 8: India Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 9: South Korea Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 10: South Korea Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 11: Bangladesh Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 12: Bangladesh Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 13: Pakistan Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 14: Pakistan Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 15: APAC Biosimilar Insulin Glargine and Lispro Pricing Analysis, 2014-2024F
Note: Product cover images may vary from those shown
3 of 3
LOADING...
4 of 3
- Sanofi S.A
- Biocon Limited
- Novo Nordisk A/S
- Wockhardt Ltd
- Eli Lily and Company
- Julphar Diabetes LLC
- SAJA Pharmaceuticals
- Gan & Lee Pharmaceutical Ltd
- Cipla Limited
- Merck & Co.
Note: Product cover images may vary from those shown
